Long-term follow-up for EG110A gene therapy patients
Part of Brain & nervous system, Injuries & trauma, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows up on people who previously received EG110A gene therapy in an earlier trial (EG110A-001-01) to monitor their health over a longer period. It helps doctors understand the lasting safety and effects of the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received at least one dose or injection of EG110A in the earlier study (EG110A-001-01).
- You have either completed that earlier study or stopped taking part early.
- You are not planning to join another experimental gene therapy study.
- You do not have any uncontrolled medical conditions or substance abuse that might interfere with following the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a nerve-stimulation approach to improve bladder control in people with spinal cord injury. It specifically targets bladder problems that require clean intermittent catheter use and includes regular testing over 6 months.
This trial tests a new gene therapy called EG110A for people with overactive bladders due to spinal cord injury. It aims to reduce urinary incontinence and may offer an option if other treatments haven't worked well.
This study follows participants who previously received the RGX-111 treatment to monitor their health over time. It helps researchers understand the long-term effects and safety of the therapy.
This study is a long-term follow-up for people with Angelman syndrome who have already taken part in a GTX-102 trial. It tests whether the treatment continues to be safe and helpful over a longer period.
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
This study follows patients who previously received IPS101A, an experimental gene therapy treatment for severe Parkinson's disease. Researchers want to check how you're doing over time and gather information about the treatment's long-term effects.
Hear when a new Urinary Bladder, Overactive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.